A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

Publisher： Karger

E-ISSN： 1423-0232|66|4|281-287

ISSN： 0030-2414

Source： Oncology, Vol.66, Iss.4, 2004-06, pp. : 281-287

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

By Yasufuku Tomihiko   Shigemura Katsumi   Matsumoto Osamu   Arakawa Soichi   Fujisawa Masato  

Journal of Infection and Chemotherapy, Vol. 16, Iss. 3, 2010-06 ,pp. : 200-205

Springer Publishing Company

Access to resources Recommend Favorite

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 7, 2007-06 ,pp. : 355-360

Karger

Access to resources Recommend Favorite

Docetaxel plus Prednisone versus Mitoxantrone plus Prednisone for Metastatic Hormone-Refractory Prostate Cancer in Chinese Patients: Experience of a Single Center

By  

Urologia Internationalis, Vol. 79, Iss. 4, 2007-11 ,pp. : 307-311

Karger

Access to resources Recommend Favorite

TREATMENT WITH PREDNISOLONE OF HORMONE-REFRACTORY PROSTATE CANCER

By Fuse H.   Nozaki T.   Fujiuchi Y.   Mizuno I.   Nagakawa O.   Okumura A.  

Archives of Andrology, Vol. 52, Iss. 1, 2006-01 ,pp. : 35-38

Informa Healthcare

Access to resources Recommend Favorite

Role of Chemotherapy in Hormone-Refractory Prostate Cancer

By  

Urologia Internationalis, Vol. 70, Iss. 1, 2003-02 ,pp. : 1-14

Karger

Access to resources Recommend Favorite